King Pharmaceuticals, Wyeth amend Altace agreement

Share this article:
King Pharmaceuticals and Wyeth have amended and restated their co-promotion agreement for King's Altace (ramipril), an angiotensin converting enzyme (ACE) inhibitor to treat high blood pressure. Effective Jan. 1, 2007, King will assume full responsibility for the selling and marketing of Altace. For the remainder of 2006, the Wyeth sales force will continue to promote the product with King, and Wyeth will receive a fee thereafter through 2010.
Share this article:

Email Newsletters

More in News

Astellas, DOJ settle for $7.3M

Astellas, DOJ settle for $7.3M

Astellas has settled a False Claims case with the Department of Justice over the 2010-2013 marketing of an antifungal medication. Astellas denies the allegations.

Boehringer drug lands US, EU orphan tag

Boehringer drug lands US, EU orphan tag

The experimental Breakthrough Therapy treatment is for acute myeloid leukemia.

Omnio app moves to smartphones

Omnio app moves to smartphones

Physicians Interactive is introducing the third wave of its Omnio app, making the tablet-only tool available for iPhones and Android phones.